Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma

Overview

Osteosarcoma is the most common primary highly malignant bone tumor in children and young people. Incidence rates are bimodal, with the first peak occurring in adolescence and the second peak in patients over 60 years of age. The 5-year survival rate of patients with osteosarcoma is less than 20%. This study aims to improve the prognosis of patients and change the outcome of patients with osteosarcoma.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 15, 2022

Detailed Description

This project intends to conduct a multicenter, randomized, double-blind, parallel-controlled clinical trial of ganoderma spore powder and doxorubicin combined with cisplatin chemotherapy in the treatment of osteosarcoma patients. The combination therapy of traditional chemotherapeutics has not played a good effect and has large side effects. The Ganoderma lucidum spore powder group is a natural botanical drug that has a good anti-tumor auxiliary effect in regulating the tumor immune microenvironment. The investigators' previous research showed that Ganoderma lucidum spore powder can inhibit the growth and metastasis of osteosarcoma in the body without obvious toxic and side effects, which indicates that this research scheme has strong feasibility.

Interventions

  • Drug: Ganoderma lucidum
    • Participants take ganoderma lucidum spore powder once a day, 1000mg
  • Drug: Chemotherapy
    • Subjects are treated with conventional chemotherapy
  • Drug: Placebos
    • Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg

Arms, Groups and Cohorts

  • Sham Comparator: sham group
    • Treated with conventional chemotherapy drugs
  • Placebo Comparator: NC group
    • Treated with conventional chemotherapy drugs and Placebo
  • Experimental: experimental group
    • Treated with conventional chemotherapy drugs and Ganoderma lucidum

Clinical Trial Outcome Measures

Primary Measures

  • Effect of 5-year survival rate of Ganoderma osteosarcoma patients
    • Time Frame: up to 60 months
    • Karnofsky (Karlfeld, KPS, percentile) functional status scoring criteria

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent form Clinical diagnosis of osteosarcoma Must be able to swallow tablets after surgical resection Exclusion Criteria:

  • Symptomatic central nervous system metastases and/or carcinomatous meningitis Known HIV or active hepatitis B/C infection Active infection requiring systemic treatment Clinically significant cardiac arrhythmias Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system < 6 months prior to screening A pregnant or nursing female, or women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception Any condition for which participation would not be in the best interest of the participant Patients unable to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures or those with severe psychiatric illness/social situations that would limit compliance with study requirements Patients participating in another clinical investigation at the time of signature of the informed consent

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.